Clinical Trial Detail

NCT ID NCT03301636
Title A Study of Indoximod or Placebo Plus Pembrolizumab or Nivolumab in Subjects With Unresectable or Metastatic Melanoma (NLG2107)
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors NewLink Genetics Corporation
Indications

melanoma

Therapies

Indoximod + Nivolumab

Indoximod + Pembrolizumab

Age Groups: adult senior

Additional content available in CKB BOOST